Janux Therapeutics Inc.

Last updated September 27, 2026
Favorite this organization

Organization details

Legal name
Janux Therapeutics Inc.
Ownership
Public
Status
Active
SIC code
2834 — Pharmaceutical Preparations
Jurisdiction of incorporation
Delaware
Headquarters city
SAN Diego
Headquarters state / province
California
Headquarters country
United States
Fiscal year end
December
Ticker symbol
JANX
Primary stock exchange
Nasdaq

Identifiers

SEC CIK
0001817713
EIN
82-2289112

Board of directors

Follow this board

Chief executives

David Alan Campbell · President and CEO
Dates unknown

Director election results

Annual meeting of June 11, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.

Board connections

7 of this board's directors also sit on 30 other boards.

Network of Janux Therapeutics Inc.'s board connections Bicara Therapeutics Inc. Bicara Therapeutics In... Jade Biosciences Inc. Jade Biosciences Inc. Parabilis Medicines Inc. Parabilis Medicines In... Septerna Inc. Septerna Inc. Tyra Biosciences Inc. Tyra Biosciences Inc. ARS Pharmaceuticals Inc. ARS Pharmaceuticals In... Acrivon Therapeutics Inc. Acrivon Therapeutics I... Acumen Pharmaceuticals Inc. Acumen Pharmaceuticals... Artiva Biotherapeutics Inc. Artiva Biotherapeutics... Black Diamond Therapeutics Inc. Black Diamond Therapeu... Climb Bio Inc. Climb Bio Inc. Evommune Inc. Evommune Inc. Freenome Inc. Freenome Inc. Hemab Therapeutics Holdings Inc. Hemab Therapeutics Hol... LENZ Therapeutics Inc. LENZ Therapeutics Inc. Mineralys Therapeutics Inc. Mineralys Therapeutics... Eric Dobmeier Eric Dobmeier Jake Simson Jake Simson Peter Kolchinsky Peter Kolchinsky Rajeev M. Shah Rajeev M. Shah Janux Therapeutics Inc.
Shared director Other board Same sector +14 more in the list below

Insider trades

All notable trades →

From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.

Bought, last 12 months
$0
0 purchases by 0 insiders
Sold, last 12 months
$1,058,002
12 sales by 7 insiders
Date Insider Transaction Shares Price Value
Jul 31, 2026 David Alan Campbell Director, Officer (President and CEO) Gift −123,840 — —
Jul 8, 2026 David Alan Campbell Director, Officer (President and CEO) Option exercise +7,000 $4.21 $29,470
Jun 11, 2026 RA Capital Nexus Fund II, L.P. Director Grant or award +5,500 — —
Jun 11, 2026 Jake Simson Director Grant or award +5,500 — —
Jun 11, 2026 Winston Kung Director Grant or award +5,500 — —
Jun 11, 2026 Natasha Hernday Director Grant or award +5,500 — —
Jun 11, 2026 Eric Dobmeier Director Grant or award +5,500 — —
Jun 11, 2026 Vickie L. Capps Director Grant or award +5,500 — —
Jun 11, 2026 Ronald W. Barrett Director Grant or award +5,500 — —
Jun 2, 2026 Doyle Janeen Noel Officer (Chief Corp. & Bus. Dev. Ofcr) Open-market sale −4,059 $14.03 $56,948
May 11, 2026 Dobek Maria Officer (Vice President, Accounting) Open-market sale −2,038 $14.17 $28,878
Feb 2, 2026 Go William Officer (Chief Medical Officer) Grant or award +44,000 — —
Jan 2, 2026 Meyer Andrew Hollman Officer (Chief Business Officer) Open-market sale −1,879 $13.73 $25,799
Jan 2, 2026 DiRaimondo Thomas Officer (Chief Scientific Officer) Open-market sale −2,505 $13.73 $34,394
Jan 2, 2026 David Alan Campbell Director, Officer (President and CEO) Open-market sale −8,072 $13.73 $110,829

Reviews (0)

Sign in to write a review.

No reviews yet. Be the first to write one.

We use cookies to run this site and, with your permission, to measure traffic and support the affiliate links that help fund it.